Home > Boards > US Listed > Medical - Healthcare > Precision Therapeutics Inc. (AIPT)

Today's release is about the relatively rare condition

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
77Port Member Profile
 
Followed By 2
Posts 181
Boards Moderated 0
Alias Born 08/27/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2019 8:46:12 AM
Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Off... GlobeNewswire Inc. - 6/12/2019 8:00:00 AM
Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc. GlobeNewswire Inc. - 6/11/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:12:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:01:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2019 5:45:51 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/24/2019 4:10:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 3:47:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:15:04 PM
Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant GlobeNewswire Inc. - 5/21/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:03:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 9:02:17 AM
Precision Therapeutics Gains Extension for Nasdaq Compliance GlobeNewswire Inc. - 5/17/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2019 4:35:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:07:54 PM
Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/15/2019 4:05:00 PM
Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019 GlobeNewswire Inc. - 5/13/2019 1:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 5:17:36 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:56:15 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:31:32 PM
Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next... GlobeNewswire Inc. - 4/18/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Dem... GlobeNewswire Inc. - 4/16/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine... GlobeNewswire Inc. - 4/11/2019 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/10/2019 5:16:33 PM
Precision Therapeutics’ Subsidiary Helomics to Collaborate with Viome to Explore the Impact of the Gut Microbiome on Ovaria... GlobeNewswire Inc. - 4/9/2019 8:45:00 AM
77Port   Thursday, 04/18/19 03:05:51 PM
Re: None
Post # of 4057 
Today's release is about the relatively rare condition called Alopecia. If AIPT/Helomics can bring together the known information into a relevant database then, perhaps, interest in Alopecia research will grow and licensing fees to AIPT/Helomics will also grow. If this is a sign of the future, and if AIPT can sign similar agreements with countless foundations representing health conditions not receiving mainstream focus and funding, then this could become a genuine center of knowledge for researchers worldwide.

Today release:
http://investors.skylinemedical.com/news-releases/news-release-details/precision-therapeutics-subsidiary-helomics-and-national-alopecia
MINNEAPOLIS and SAN RAFAEL, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation (NAAF), which serves the community of people affected by an autoimmune skin disease called alopecia areata that results in hair loss and emotional pain, to provide a next generation patient registry to drive research into new treatments for people with this disease.

“This agreement will provide NAAF with the ability to store, process and analyze specimens under one roof and in a CLIA regulated setting,” said Gerald Vardzel, president of Helomics. “This approach is a one-stop-shop for all aspects of the specimen lifecycle that will save costs, improve specimen quality, and make available the latest NGS testing to researchers looking into the underlying molecular mechanisms of alopecia areata, while leveraging our D-CHIP platform toward these rich data.”

Helomics will leverage its CRO and Biorepository services offering to provide state of the art storage, processing and analysis of samples from patients with alopecia areata who newly enroll with the NAAF registry, as well as storing samples from the existing registry. The registry was originally established in 2000 by a collaborative group of five experienced hair disease investigators and supported for 12 years by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under Award Number HHSN268200682279C. Registry samples and analytical services such as Next Generation Sequencing (NGS) will be made available to NAAF-sponsored researchers on request. The companies will also explore the application of the Helomics D-CHIP Artificial intelligence (AI) platform to data generated as part of the registry. Terms and financial conditions of the agreement were not disclosed.

Dory Kranz, president and CEO of NAAF added, “Achieving better outcomes for people with alopecia areata is a key part of the mission of NAAF and working with Helomics to provide this registry to our researchers is a key step. We are hopeful that in the future, applying Helomics’ AI and machine learning capabilities to the valuable data and samples we collect, will lead to a better understanding and improved treatments for alopecia areata, and other autoimmune diseases. All parties are excited about building on this valuable resource.”

“Agreements such as this one with NAAF further validate the Helomics boutique CRO services business and our D-CHIP AI-driven platform. We are enthusiastic about the opportunity to serve the alopecia areata community and look forward to a long term and impactful partnership,” concluded Dr. Carl Schwartz, president and CEO of Precision Therapeutics.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist